

Supplementary file

Supplementary Table 1. Predictors of asymptomatic SARS-CoV-2 infection among SARS-CoV-2 patients admitted to two hospitals in Uganda

Factor	Asymptomatic	Symptomatic	P-value	Odds Ratio (95% CI)
Overall, N (%)	32 (57.1)	24 (42.9)		
Age	N=31	N=24		
Median (IQR)	33 (25, 54)	32.5 (25, 38)	0.355 [°]	1.02 (0.99 – 1.06)
Sex	N=32	N=24		
Female, n (%)	11 (34.4)	7 (29.1)	0.680 [¶]	1.27 (0.41 – 3.99)
SPO2	N=29	N=22		
Median (IQR)	98 (97, 99)	98 (97, 99)	0.890 [°]	1.00 (0.99 – 1.01)
Pulse rate	N=31	N=23		
Median (IQR)	83 (76, 92)	90 (82, 96)	0.067 [°]	0.97 (0.93 – 1.01)
Blood Pressure	N=31	N=22		
>130/90, n (%)	11 (35.5)	9 (39.1)	0.784 [¶]	0.86 (0.28 – 2.61)
Comorbidities	N=32	N=24		
Any comorbidity, n (%)	8 (25.0)	7 (29.2)	0.728 [¶]	0.81 (0.25 – 2.66)
Tuberculosis, n (%)	0 (0.0)	1 (4.2)	0.429 [†]	---
Heart disease (CVD), n (%)	2 (6.3)	3 (12.5)	0.642 [†]	0.47 (0.07 – 3.04)
Asthma, n (%)	0 (0.0)	2 (8.3)	0.179 [†]	---
COPD, n (%)	0 (0.0)	1 (4.2)	0.429 [†]	---
Diabetes, n (%)	3 (9.4)	3 (12.5)	>0.999 [†]	0.72 (0.13 – 3.95)
Hypertension, n (%)	5 (15.6)	1 (4.2)	0.223 [†]	4.26 (0.46 – 38.13)
Cancer, n (%)	0 (0.0)	1 (4.2)	0.429 [†]	---
HIV, n (%)	1 (3.1)	3 (12.5)	0.303 [†]	0.23 (0.02 – 2.32)
Lymphocyte count	N=25	N=20		
Median (IQR)	2.4 (1.8, 2.9)	2.3 (1.7, 2.9)	0.909 [°]	1.05 (0.51 – 2.16)
Platelets	N=9	N=10		
Median (IQR)	188 (121, 275)	244 (168, 272)	0.838 [°]	1.00 (0.99 – 1.01)
ALT	N=27	N=20		
Median (IQR)	16.3 (13.5, 33.3)	15.6 (13.8, 24.8)	0.707 [°]	1.01 (0.97 – 1.04)
AST	N=27	N=20		
Median (IQR)	24.1 (19.4, 29.9)	22.9 (19.1, 28.2)	0.598 [°]	1.00 (0.96 – 1.04)
Bilirubin	N=6	N=9		
Median (IQR)	5.8 (2.4, 13.8)	0 (0, 11.7)	0.301 [°]	1.05 (0.95, 1.16)

Supplementary Table 2. Hydroxychloroquine side effects among SARS-CoV-2 patients admitted to two hospitals in Uganda by site

Side effect (at least once during follow up)	All n (%) N=50	Mulago Hospital n (%) N=22	Entebbe Hospital n (%) N=28	p-value [†]
Diarrhea	3 (6.0)	2 (9.1)	1 (3.6)	0.576
Vomiting	2 (4.0)	1 (4.6)	1 (3.6)	>0.999
Nausea	4 (8.0)	1 (4.6)	3 (10.7)	0.621
Abdominal pain	4 (8.0)	1 (4.6)	3 (10.7)	0.621
Loss of appetite	3 (6.0)	1 (4.6)	2 (7.1)	>0.999
Jaundice	1 (2.0)	0	1 (3.6)	>0.999
Aspartate aminotransferase >40 U/liter	5 (10.0)	4 (18.2)	1 (3.6)	0.155
Alanine aminotransferase >40 U/liter	6 (12.0)	5 (22.7)	1 (3.6)	0.075
Total bilirubin >17.1 µmol/liter	12 (24.0)	2 (9.1)	10 (35.7)	0.045
Headache	2 (4.0)	1 (4.6)	1 (3.6)	>0.999
Dizziness	1 (2.0)	0	1 (3.6)	>0.999
ringing in your ears	0	0	0	---
Blurred vision	0	0	0	---
Palpitations	0	0	0	---
Bradycardia	1 (2.0)	1 (4.6)	0	0.440
New onset Hypertension	4 (8.0)	4 (18.2)	0	0.032
Fatigue	2 (4.0)	1 (4.6)	1 (3.6)	>0.999
Joint or muscle pain	2 (4.0)	0	2 (7.1)	0.497
Rash, pruritus	3 (6.0)	1 (4.6)	2 (7.1)	>0.999
Pigmentary changes in skin and mucous membranes	0	0	0	---
New onset Fever	0	0	0	---
White cell count, count ≤4000/mm ³	6 (12.0)	5 (22.7)	1 (3.6)	0.075
thrombocytopenia, count <150,000 per mm ³	5 (10.0)	2 (9.1)	3 (10.7)	>0.999
Lymphopenia , count ≤1500/mm ³	0	0	0	---
Neutropenia	22 (44.0)	10 (45.5)	12 (42.9)	0.854 ^{††}
Hypoglycemia	2 (4.0)	1 (4.6)	1 (3.6)	>0.999
Affect liability	5 (10.0)	5 (22.7)	0	0.012
Corrected QT interval (QTc) >60 ms	0	0	0	---
Atrioventricular block	1 (2.0)	1 (4.6)	0	0.440

Supplementary Table 3. Comorbidities among patients infected with SARS-CoV-2 admitted to two hospitals in Uganda

Comorbidities, n (%)	N=56	N=25	N=31	
Any	15 (26.8)	10 (40.0)	5 (16.1)	0.069 [¶]
Tuberculosis	1 (1.8)	0 (0.0)	1 (3.2)	>0.999 [†]
Heart disease (CVD)	5 (8.9)	4 (16.0)	1 (3.2)	0.161 [†]
Hypertension	6 (10.7)	4 (16.0)	2 (6.5)	0.391 [†]
Asthma	2 (3.6)	0 (0.0)	2 (6.5)	0.497 [†]
COPD	1 (1.8)	0 (0.0)	1 (3.2)	>0.999 [†]
Diabetes	6 (10.7)	5 (20.0)	1 (3.2)	0.079 [†]
Cancer	1 (1.8)	0 (0.0)	1 (3.2)	>0.999 [†]
HIV	4 (7.1)	1 (4.0)	3 (9.7)	>0.620 [†]
Chronic kidney disease	1 (1.8)	0 (0.0)	1 (3.2)	>0.999 [†]
Chronic liver disease	1 (1.8)	0 (0.0)	1 (3.2)	>0.999 [†]
Chronic neurological disorder	1 (1.8)	0 (0.0)	1 (3.2)	>0.999 [†]
Others	1 (1.8)	1 (4.0)	0 (0.0)	0.446 [†]